All In Biotech

Drug Trial Radar · NCT04856969

Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Cross-over Design Clinical Trial to Evaluate the Safety and Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Mar 30, 2021

Primary completion

May 4, 2021

Study completion May 4, 2021

Sponsor

Lead sponsor
AutotelicbioIndustry
Sponsor type
Industry
First posted
Apr 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the interaction between two investigational products by comparing and analyzing pharmacokinetic interactions and safety in steady state after multiple oral administration of ATB-1011 or ATB-1012 alone or in combination in healthy adult volunteers.

Conditions

  • Healthy Adult Volunteers

Interventions

  • OlmesartanDrug

    First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

  • DapagliflozinDrug

    First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ATB-1011 AUCτ,ssTime frame: 5days, 10days
  2. ATB-1012 AUCτ,ss,Time frame: 5days, 10days
  3. ATB-1011 Cmax,ssTime frame: 5days, 10days
  4. ATB-1012 Cmax,ssTime frame: 5days, 10days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H Plus Yangji Hospital

    Seoul, Gwanak-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.